Onset and Early Behavioral Effects of Pharmacologically Different Antidepressants and Placebo in Depression
The DOI matches its Crossref record; 70 of the 72 references it cites were found in a registry or an index.
Abstract
This study was aimed at resolving the time course of clinical action of antidepressants (ADs) and the type of early behavioral changes that precede recovery in treatment-responsive depressed patients. The first goal was to identify, during the first 2 weeks of treatment, the onset of clinical actions of the selective serotonin reuptake inhibitor (SSRI), paroxetine, and the selective noradrenergic reuptake inhibitor, desipramine (DMI). The second aim was to test the hypothesis that the two pharmacologic subtypes would induce different early behavioral changes in treatment-responsive patients. The design was a randomized, parallel group, placebo-controlled, double-blind study for 6 weeks of treatment following a 1-week washout period. The study utilized measures of the major behavioral components of the depressive disorder as well as overall severity. The results indicated that the onset of clinical actions of DMI ranged from 3 to 13 days, averaged 13 days for paroxetine, and was 16-42 days for placebo. Furthermore, as hypothesized, the different types of ADs initially impacted different behavioral aspects of the disorder. After 1 week of treatment, DMI produced greater reductions in motor retardation and depressed mood than did paroxetine and placebo, and this difference persisted at the second week of treatment. Early improvement in depressed mood-motor retardation differentiated patients who responded to DMI after 6 weeks of treatment from those that did not. Paroxetine initially reduced anxiety more in responders than in nonresponders, and by the second week, significantly improved depressed mood and distressed expression in responders to a greater extent. Depressed patients who responded to placebo showed no consistent early pattern of behavior improvement. Early drug-specific behavioral changes were highly predictive of ultimate clinical response to the different ADs, results that could eventually be applied directly to clinical practice.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Some users react differently to the same antidepressant [19] while different antidepressants produce different effects [20].”
From ‘In my life antidepressants have been…’: a qualitative analysis of users’ diverse experiences with antidepressants (2016) · cites this paper as [20]
Citations
Cites
Statistical Power Analysis for the Behavioral Sciences
Muller, K. (1989) · Technometrics · doi:10.1080/00401706.1989.10488618 · Cited by 99,167
Statistical power analysis for the behavioral sciences
(1990) · Computers, Environment and Urban Systems · doi:10.1016/0198-9715(90)90050-4 · Cited by 65,269
(1990) · Choice Reviews Online · doi:10.5860/choice.27-3338 · Cited by 35,305
Hamilton, M. (1960) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.23.1.56 · Cited by 32,817 · cited 1×
“(Hamilton, 1960).”
Random-Effects Models for Longitudinal Data
Laird, N. M., & Ware, J. H. (1982) · Biometrics · doi:10.2307/2529876 · Cited by 8,923 · cited 1×
“To determine if one drug acts faster than the other and/ or placebo in reducing the overall severity or specific symptomatic behaviors during this 2-week treatment period, the linear mixed model (Laird and Ware, 1982) was used to model the longitudinal change in each construct.”
MethodKupper, L. L., Hosmer, D. W., & Lemeshow, S. (1990) · Journal of the American Statistical Association · doi:10.2307/2290035 · Cited by 7,599
A Diagnostic Interview: The Schedule for Affective Disorders and Schizophrenia
Endicott, J. (1978) · Archives of General Psychiatry · doi:10.1001/archpsyc.1978.01770310043002 · Cited by 5,684 · cited 2×
“…approach (Katz et al, 1984), doctor ratings included the Ham-D, CGI, Schedule for Affective Disorders, and SchizophreniaChange Version (SADS-C, Endicott and Spitzer, 1978), Global Assessment Scale (GAS, Endicott et al, 1976), Video Interview Behavioral Evaluation Scales (VIBES) (Katz and…”
MethodThe Global Assessment Scale: A Procedure for Measuring Overall Severity of Psychiatric Disturbance
Endicott, J. (1976) · Archives of General Psychiatry · doi:10.1001/archpsyc.1976.01770060086012 · Cited by 4,982 · cited 1×
“…Ham-D, CGI, Schedule for Affective Disorders, and SchizophreniaChange Version (SADS-C, Endicott and Spitzer, 1978), Global Assessment Scale (GAS, Endicott et al, 1976), Video Interview Behavioral Evaluation Scales (VIBES) (Katz and Itil, 1974); nurse ratings: the Affective Disorder Rating Scale…”
BackgroundAn inventory for assessing different kinds of hostility.
Buss, A. H., & Durkee, A. (1957) · Journal of Consulting Psychology · doi:10.1037/h0046900 · Cited by 2,575 · cited 2×
“…(Murphy et al, 1980), NIMH Mood Scale (Raskin et al, 1969), Global Ward Behavior Scale (Raskin et al, 1969); patient self-reports included the Symptoms Checklist (SCL-90; Derogatis et al, 1974); NIMH Mood Scale (Raskin et al, 1969); and the Buss–Durkee Hostility Inventory (Buss and Durkee, 1957).”
MethodWillner, P. (1997) · Psychopharmacology · doi:10.1007/s002130050456 · Cited by 1,832 · cited 1×
“This later behavioral effect of paroxetine may not be due to serotonin exclusively, but to sequential or direct interactions between serotonin and noradrenergic or even dopaminergic systems (Willner, 1997; Bonhomme and Esposito, 1998; Bourin et al, 2001).”
Background
Research works printed but not linked: 3
- Guy W (1976). Early clinical drug evaluation program (ECDEU). In: Assessment Manual of Psychopharmacology. Department of Health, Education and Welfare: Rockville MD.
- Murphy DL, Pickar D, Alterman JS (1980). Methods for the quantitative assessment of depressive and manic behavior. In: Burdock EJ, Sudilovsky A, Gershon S (eds) Quantitative Techniques for the Evaluation of the Behavior of Psychiatric Patients. Marcel-Decker: New York, 355–392.
- Spitzer RL, Williams JBW (1983). Instruction manual For the Structured Clinical Interview for DSM III (SCID), Revision. Biometrics Research Department, M.Y. State Psychiatric Institute: New York.
Cited by
Items 201–266 of 266
Sex Differences in the Antidepressant Effects of Ketamine in Animal Models of Depression
Adu‐Nti, F., George, G.-K., & Benjamin, A. (2019) · International Journal of Depression and Anxiety · doi:10.23937/2643-4059/1710013 · Cited by 5
Next generation antidepressants with novel mechanisms for treatment resistant depression
Chen, M., Tu, P., & Su, T. (2023) · Progress in brain research · doi:10.1016/bs.pbr.2023.02.005 · Cited by 3
Case report: two cases of rhabdomyolysis following esketamine treatment
Zeiss, R., Schweizer, M., Connemann, B. J., & Malejko, K. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2024.1450092 · Cited by 3
Vigliecca, N. S., Molina, S. C., & Peñalva, M. C. (2006) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/j.vascn.2006.02.008 · Cited by 3
Early Prediction of the Effectiveness of Antidepressants: Inputs from an Animal Model
Friedman, A., Merenlender, A., Lax, E., Rosenstein, M., Lubin, N., & Yadid, G. (2009) · Journal of Molecular Neuroscience · doi:10.1007/s12031-009-9176-9 · Cited by 3
“Furthermore, antidepressants must usually be taken for several weeks before significant therapeutic effects are identified (Chesen and Gelenberg 2002; Katz et al. 2004; Taylor et al. 2006; Papakostas et al. 2006; Wade and Friis Andersen 2006; Gershon et al. 2007).”
BackgroundClinical Trials of Antidepressants: Time to Shift to a New Model
Katz, M. M. (2008) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31817d8713 · Cited by 3
Self-citationMethods to improve the efficiency of confirmatory clinical trials
Boessen, R. (2013) · Utrecht University Repository (Utrecht University) · Cited by 3
Görnert, C., Scherf‐Clavel, M., Weber, H., Roll, S. C., Eckert, A., Reif, A., & Hahn, M. (2026) · The Pharmacogenomics Journal · doi:10.1038/s41397-026-00407-3 · Cited by 2
“The clinical response to AD typically occurs within 14 days, and initial ADR usually subside after this period [48].”
Targum, S. D., Sanacora, G., Formella, A. E., Ceresoli‐Borroni, G., & Owen, R. (2026) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2026.01.006 · Cited by 2
Esketamine Nasal Spray: Mechanism of Action, Clinical, and Translational Science
van Hoogdalem, M. W., Fu, D., Drevets, W. C., & Zannikos, P. (2026) · Clinical and Translational Science · doi:10.1111/cts.70527 · Cited by 2
Tzavara, E. T., & Witkin, J. J. M. (2007) · Springer eBooks · doi:10.1007/978-0-387-74349-3_23 · Cited by 2
“In addition, although antidepressant effects of compounds can be seen rather soon after dosing, the full efficacy of these compounds is generally observed only after several weeks of treatment (Katz et al., 2004), leaving the risk of suicide incompletely managed.”
BackgroundThe Componential Approach Enhances the Effectiveness of 2-Week Trials for New Antidepressants
Katz, M. M., Berman, N., Bowden, C. L., & Frazer, A. (2011) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3182103461 · Cited by 2
Self-citationMolina, L., Recinos, B., Paz, B., Rovelo, M., Elias, F. E. R., Calderón, J., Arellano, A., Pomata, S., Rey, M. V., & Perez‐Lloret, S. (2016) · Clinical Drug Investigation · doi:10.1007/s40261-016-0395-x · Cited by 2
“show a bad outcome with prolonged treatment [8, 26].”
BackgroundAdongo, D. W., Mante, P. K., Kukuia, K. K. E., & Woode, E. (2016) · International Journal of Basic & Clinical Pharmacology · doi:10.18203/2319-2003.ijbcp20162426 · Cited by 3
Menezes, C. E. D. S., McIntyre, R. S., Filho, A. J. M. C., Vasconcelos, S. M. M., de Sousa, F. C. F., Quevedo, J., Hyphantis, T. N., Carvalho, A. F., & Macêdo, D. S. (2018) · Pharmacological Reports · doi:10.1016/j.pharep.2018.07.003 · Cited by 2
Trepl, J., Dahlmanns, M., Kornhuber, J., Groemer, T. W., & Dahlmanns, J. K. (2022) · Journal of Neural Transmission · doi:10.1007/s00702-022-02477-6 · Cited by 2
“Many currently available antidepressant drugs (ADDs) are selective monoamine reuptake inhibitors, which often take weeks to months to show clinical effects (Nestler et al. 2002; Katz et al. 2003; Rush et al. 2006).”
BackgroundZhao, Z. (2008) · The Research Repository @ WVU (West Virginia University) · doi:10.33915/etd.2697 · Cited by 2
Autonomous and motor behaviors
Crusio, W. E., Sluyter, F., Gerlai, R. T., & Pietropaolo, S. (2013) · Cambridge University Press eBooks · doi:10.1017/cbo9781139541022.011 · Cited by 1
Katz, M. M., Berman, N., Bowden, C. L., & Frazer, A. (2015) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000317 · Cited by 1
“Assessments of changes in dimensions of the disorder were conducted using the MV method described in detail in the study of Katz et al.11,13 The method was validated using MDD patient and healthy control samples used in the multisite collaborative study of the psychobiology of depression.14 If the proportion of EIs in…”
MethodSelf-citationGarg, R., Kapoor, A., Chavan, B., & Kaur, P. (2015) · Journal of Mental Health and Human Behaviour · doi:10.4103/0971-8990.174590 · Cited by 1
Possible Solutions to Depression Using BCI Methods
Bai, L. (2023) · Highlights in Science Engineering and Technology · doi:10.54097/hset.v39i.6575 · Cited by 1
Perspective for new pharmacological interventions
Bowden, C. L. (2016) · Cambridge University Press eBooks · doi:10.1017/cbo9781107477278.020 · Cited by 1
Self-citationNeuron-Glia Signaling Regulates the Onset of the Antidepressant ResponsePreprint
Yao, V., Aly, A., Kalik, S., Gresack, J. E., Wang, W., Handler, A., Schaefer, A., Troyanskaya, O. G., Greengard, P., & Chottekalapanda, R. U. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.07.23.453443 · Cited by 1
“Importantly, clinical data indicates that responders to treatment show signs of improvement at day 10 of treatment 11, 57-59 , an early time window when we document adaptations in multiple neuronal populations.”
BackgroundPerspectives for New Pharmacological Interventions
Bowden, C. L. (2007) · Medical psychiatry · doi:10.3109/9781420021158.020 · Cited by 1
Self-citationWitkin, J. M. (2010) · Birkhäuser Basel eBooks · doi:10.1007/978-3-0346-0241-9_4 · Cited by 1
“When imipramine was combined with LY341495 or a low dose of the mGlu2/3 agonist LY379268, neuroadaptation to imipramine (change in b1 adrenoceptor expression) occurred at shorter times than with imipramine alone [32], suggesting the possibility that mGlu2/3 receptor ligands might shorten the time required to exert ful…”
BackgroundVigliecca, N. S., Molina, S. C., & Peñalva, M. C. (2007) · Investigación Clínica
Katz, M. M. (2009) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31819cdf34
Self-citationTesting New Hypotheses About Neurochemistry, Depression, and Drugs
Katz, M. M. (2013) · SpringerBriefs in psychology · doi:10.1007/978-3-319-00389-4_7
Self-citationLes effets précoces des antidépresseurs
Llorca, P. (2012) · L Encéphale · doi:10.1016/s0013-7006(12)70076-3
“[4] ont, à partir d’une méta-analyse, identifi é 11 dimensions cliniques (humeur”
Mechanisms of antidepressant action: is onset early or late?
Frazer, A., & Katz, M. M. (2004) · Drug Discovery Today Disease Mechanisms · doi:10.1016/j.ddmec.2004.11.019
Self-citationKatz, M. M. (2013) · SpringerBriefs in psychology · doi:10.1007/978-3-319-00389-4_6
Self-citationWHO RECEIVES ANTIDEPRESSANTS AND WHAT IMPACT DO THEY HAVE? AN ACUTE-CARE STUDY
Averill, P. M., & Wassef, A. A. (2006) · Psychiatric Quarterly · doi:10.1007/s11126-006-9003-1
Gershenfeld, H. K. (2013) · Cambridge University Press eBooks · doi:10.1017/cbo9781139541022.020 · Cited by 1
Siva ManiMala, Y., Gautam, S., & Goutham Reddy, B. (2016) · Research and reviews : journal of pharmacology and toxicological studies
“Rashomon” and the Componential Approach to Developing Measures of Mood and Behavior
Katz, M. M. (2013) · SpringerBriefs in psychology · doi:10.1007/978-3-319-00389-4_4
Self-citationMcLaughlin, P., & Cleare, A. J. (2020) · Cambridge University Press eBooks · doi:10.1017/9781911623465.009
Carratalá‐Ros, C. (2020) · Tesis Doctorals en Xarxa (Consorci de Serveis Universitaris de Catalunya) · doi:10.6035/14109.2020.368729
Rotolo, R. A. (2020) · OpenCommons at University of Connecticut (University of Connecticut) · Cited by 2
A New Mechanism of Serotonin Transporter Regulation by Simvastatin and the Isoprenylation Pathway
Deveau, C. (2021) · IUScholarWorks (Indiana University) · doi:10.7912/c2/343 · Cited by 1
Szegedi, A., Schwertfeger, N., & Benkert, O. (2008) · Springer eBooks · doi:10.1007/978-3-540-68748-1_42 · Cited by 1
(2006) · Wiley eBooks · doi:10.1002/9780470041000.cedt080
(2006) · Wiley eBooks · doi:10.1002/9780470041000.cedt077
Mitchell, A. J. (2006) · The British Journal of Psychiatry · doi:10.1192/bjp.188.6.587
Katz, M. M. (2013) · SpringerBriefs in psychology · doi:10.1007/978-3-319-00389-4_1
Self-citationCurrent awareness in human psychopharmacology
(2004) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.568
Scharfman, H. E. (2023) · eLife · doi:10.7554/elife.86022.sa0
Effect of acupuncture on somatic symptom disorder: a systematic review and meta-analysis
Zhao, F., Wang, W., Feng, X., Li, J., Gang, W.-J., Jing, X., Chen, H., & Liang, Y. J. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1625230
Fagiolini, A. M., Reines, E. H., Farovik, A., & Areberg, J. (2025) · Annals of General Psychiatry · doi:10.1186/s12991-025-00598-2
“It is generally accepted that most oral antidepressants take between 2 and 4 weeks to see a full antidepressant effect [9, 10].”
Developing a More Effective and More Efficient Clinical Trial Model
Katz, M. M. (2013) · SpringerBriefs in psychology · doi:10.1007/978-3-319-00389-4_8
Self-citationBryant, E. M. (2023) · UNSWorks (University of New South Wales, Sydney, Australia) · doi:10.26190/unsworks/24969
Longitudinal Investigation of Phenotypic, Genetic and Epigenetic Factors in Mood Disorders
Sirignano, L. (2024) · heiDOK (Heidelberg University) · doi:10.11588/heidok.00035568
Elaboration of the New Theory of Depression and Conclusions
Katz, M. M. (2013) · SpringerBriefs in psychology · doi:10.1007/978-3-319-00389-4_9
Self-citationIntravenous Ketamine Infusion for Major Depressive Disorder: A Case Series Analysis
Gadad, A., Shettar, M., Nadadgalli, G., & Narayanan, N. (2026) · Annals of Indian Psychiatry · doi:10.4103/aip.aip_234_25
Wood, B. J., Vest, M. F., Carfagno, C., Bartley, K. R., Sharma, P., Halberstadt, A. L., Blough, B. E., & Murnane, K. S. (2026) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.5c00484
Parésys, L. (2015) · theses.fr (ABES) · doi:10.70675/cb3a1f33z6c64z4692z91cez73d3c9db9fec
“Le délai d’action des antidépresseurs se situe entre 3 semaines pour la désipramine (ATC) et 13 jours pour la paroxétine (ISRS) (Katz et al. 2004).”
BackgroundCaractérisation neuro-computationnelle de l'humeur : causes et conséquences
Carrillo, P. (2024) · theses.fr (ABES) · doi:10.70675/181aec0cz429dz4bccz83f0za479cbef52f7
Meng, L., Ji, J., Zhang, H., Cui, Z., & Yang, Y. (2026) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2026.1889208
Metadata
- Authors
- Katz, M. M., Tekell, J. L., Bowden, C. L., Brannan, S., Houston, J. P., Berman, N., & Frazer, A.
- Affiliations
- The University of Texas at San Antonio Health Science Center (US)
- Dallas VA Medical Center (US)
- Harbor–UCLA Medical Center (US)
- Corresponding author
- Frazer, Alan
- ORCID
- Frazer, Alan
- Venue
- Neuropsychopharmacology
- Published
- 2003-11-19
- Volume
- 29
- Issue
- 3
- Pages
- 566-579
- ISSN
- 0893-133X (ISSN-L)
- 1740-634X
- OpenAlex
- W2319982487
- Cited by
- 252
- References
- 72
- Citations by year
- 2026: 6 · 2025: 4 · 2024: 7 · 2023: 10 · 2022: 9 · 2021: 11 · 2020: 11 · 2019: 8 · 2018: 11 · 2017: 8 · 2016: 14 · 2015: 13 · 2014: 10 · 2013: 20 · 2012: 7
- FWCI
- 5.14
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Neuropsychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- University of Texas Health Science Center at San Antonio
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Keywords
- antidepressant onset of action, depression, paroxetine, desipramine, selective serotonin reuptake inhibitors, noradrenergic reuptake inhibitors, placebo response, motor retardation, depressive mood, anxiety, treatment response prediction
- MeSH terms
- Adult, Affect, Aged, Analysis of Variance, Antidepressive Agents, Depressive Disorder, Major, Major Depressive Disorder, Desipramine, Double-Blind Method, Female, Humans, Male, Middle Aged, Motor Activity, Time Factors, Placebo Effect, Chi-Square Distribution, Logistic Models, Paroxetine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.